Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Rothen

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Ophthalmology Clinics of North America|November 30, 2005
Anti-macular degeneration agentsMichelle Rothen, Eric Jablon, Gerardo Monares, et al.
Current Diabetes Reviews|January 29, 2008
Intravitreal triamcinolone for the treatment of diabetic macular edemaFrancisco Gómez-Ulla, Joaquín Marticorena, D Virgil Alfaro, et al.
Journal of Diabetes and Its Complications|April 17, 2008
Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohortAlicia J Jenkins, Michelle Rothen, Richard L Klein, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Ophthalmology Clinics of North America|November 30, 2005
Anti-macular degeneration agentsMichelle Rothen, Eric Jablon, Gerardo Monares, et al.
Current Diabetes Reviews|January 29, 2008
Intravitreal triamcinolone for the treatment of diabetic macular edemaFrancisco Gómez-Ulla, Joaquín Marticorena, D Virgil Alfaro, et al.
Journal of Diabetes and Its Complications|April 17, 2008
Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohortAlicia J Jenkins, Michelle Rothen, Richard L Klein, et al.
Pageof 1